United States Genome Editing Engineering Market Overview
As per MRFR analysis, the United States Genome Editing Engineering Market Size was estimated at 3.12 (USD Billion) in 2023. The United States Genome Editing Engineering Market Industry is expected to grow from 3.70 (USD Billion) in 2024 to 13.69 (USD Billion) by 2032. The Market CAGR (growth rate) is expected to be around 15.63% during the forecast period (2024 - 2032). Expanding use of CRISPR genome editing technology across a range of scientific domains and rising demand for synthetic genes are the main market drivers anticipated to propel the United States genome editing engineering market.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
United States Genome Editing Engineering Market Trends
-
Rising demand for synthetic genes is driving the market growth
The United States market's growth has mostly been fueled by rising demand for synthetic genes and rising use of CRISPR genome editing technology across a range of biotechnology industries. Rising government financing, a rise in the output of genetically modified crops, and an increase in the number of genomics projects are also expected to contribute to the market CAGR growth. CRISPR-based diagnostic techniques that have aided in COVID-19 diagnosis are another factor driving the growth. In March 2021, for instance, a team of researchers from Nanyang Technological University developed the VaNGuard (Variant Nucleotide Guard) diagnostic test in the United States. The diagnostics sector will employ CRISPR genome editing technology more frequently as a result of this test's capacity to detect mutant strains of SARS-CoV-2.
Furthermore, the capacity of the gene-editing technology market to turn a profit is significantly influenced by ongoing technological advancements. In April 2021, for instance, researchers at Harvard's Wyss Institute for Biologically Inspired Engineering developed Retron Library Recombine ring (RLR). Editing rates increased because millions of genetic tests could be conducted simultaneously thanks to this new gene-editing technology. With more government backing and financing for scientific research and development, the United States commanded the biggest market share for genome editing technologies.
It is also expected that the presence of significant players like Editas Pharmaceuticals, Thermo Fisher Scientific, and CRISPR Therapeutics, as well as rising investment in genomic research, will drive market expansion in this region Additionally, a methodology for using the CRISPR-based Specific High Sensitivity Enzymatic Reporter Unlocking (SHERLOCK) technology to identify COVID-19 has been released by researchers at the Broad Institute of MIT and Harvard. This new method detects the COVID-19 target sequences by using artificial COVID-19 virus RNA fragments. These sequences can be found in the region of 20–200 aM. Therefore, the market is expected to grow as a result of research and educational institutions' continued development of new CRISPR editing tools.
United States Genome Editing Engineering Market Segment Insights
-
United States Genome Editing Engineering Technology Insights
The United States Genome Editing Engineering market segmentation, based on Technology, includes Meganucleases, Cas9, TALENs/MegaTALs, ZFN, and Others. The Cas9 segment dominated the market mostly. This technique is helpful for gene therapy, the creation of novel medications, and scientific study since it can precisely split DNA strands and introduce new genetic material. Because of its versatility, ease of use, high efficiency, and precision, CRISPR/Cas9 is a well-liked substitute for genome editing in a variety of contexts.
-
United States Genome Editing Engineering Delivery Method Insights
The United States Genome Editing Engineering market segmentation, based on Delivery Method, includes Ex-vivo and In-vivo. Ex-vivo generated the most income. This is explained by the benefits this mode type provides, namely easy control over DNA modification. With more people using this distribution strategy, the ex-vivo delivery segment has grown as a result of the expanding clinical trial pipeline that makes use of genome processing tools.
-
United States Genome Editing Engineering Mode Insights
The United States Genome Editing Engineering market segmentation, based on Mode, includes Contract and In-house. The contract segment dominated the market mostly. This can be linked to the high level of outsourcing in the gene editing industry, which is motivated by the reduced expenses and more operational flexibility that these activities provide in comparison to in-house development. The segment is anticipated to continue growing.
-
United States Genome Editing Engineering End-use Insights
The United States Genome Editing Engineering market segmentation, based on End-use, includes Biotechnology & Pharmaceutical Companies, Academic & Government Research Institutes, and Contract Research Organizations. The biotechnology & pharmaceutical companies generated the most income. The primary cause of revenue generation is the existence of an increasing amount of research activities for the development of novel therapeutics. In addition, multinational pharmaceutical corporations are working with startup businesses to create innovative technologies.
-
United States Genome Editing Engineering Application Insights
The United States Genome Editing Engineering market segmentation, based on Application, includes Genetic Engineering and Clinical Applications. The genetic engineering segment dominated the market mostly. This is because the science of stem cell and gene therapy is expanding quickly. The use of CRISPR gene editing in programs pertaining to human induced pluripotent stem cells (hiPSCs) has significant ramifications for stem cell research for the treatment of different disorders.
Figure 1: United States Genome Editing Engineering Market, by Application, 2022 & 2032 (USD Billion)
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
United States Genome Editing Engineering Country Insights
Market expansion is fueled by ongoing developments in genome editing technologies, such as CRISPR-Cas9, TALENs, and zinc finger nucleases, which the United States enhances gene editing procedures' accuracy, effectiveness, and user-friendliness. Growing public awareness of genome editing's potential applications in agriculture, healthcare, and other fields encourages acceptance and implementation of these technologies, which in turn fuels demand in the market.
The United States As per the deal, CRISPR Therapeutics will provide its genome editing knowledge, while Capsida will offer its adeno-associated virus (AAV) delivery technology. With the accomplishment of the Human Genome Project (HGP), around 7,000 new genetic disorders affecting humans have been identified. Although gene treatments based on ex vivo gene editing, such as CAR-T, have had a substantial impact. Moreover, in the United States, the majority of patients with hereditary illnesses need in vivo therapies.
United States Genome Editing Engineering Key Market Players & Competitive Insights
Leading market players are putting a lot of money into R&D to increase the range of products they sell, which will encourage further growth in the United States Genome Editing Engineering sector. Additionally, market players are engaging in a range of calculated actions to increase their presence, with important market developments including releases of new products, contracts, acquisitions and mergers, increased investments, and cooperation with other enterprises. To grow and endure in a market that is becoming more and more competitive, the United States Genome Editing Engineering industry must provide reasonably priced goods.
Major players in the United States Genome Editing Engineering market are making investments in R&D operations in an effort to boost market demand, including Intellia Therapeutics, Inc., Caribou Biosciences, Inc., Cellectis S.A., AstraZeneca, Takara Bio USA, Horizon Discovery Group plc, Integrated DNA Technologies, Inc., Egenesis Inc.
Key Companies in the United States Genome Editing Engineering market include
- Merck KGaA
- Cibus
- Sangamo
- Editas Medicine
- Precision Biosciences
- CRISPR Therapeutics
- Intellia Therapeutics, Inc.
- Caribou Biosciences, Inc.
- Cellectis S.A.
- AstraZeneca
- Takara Bio USA
- Horizon Discovery Group plc
- Integrated DNA Technologies, Inc.
- Egenesis Inc.
- GenScript
- New England Biolabs
- OriGene Technologies, Inc.
- Lonza
- Thermo Fisher Scientific, Inc.
United States Genome Editing Engineering Industry Developments
January 2022: Pfizer, a global pharmaceutical and biotechnology company with headquarters in the United States, and Beam Therapeutics, a Massachusetts-based company that was first to create CRISPR editing tools, have agreed to a $300 million, four-year contract.
June 2021: The biotechnology firm Regeneron Pharmaceuticals, with its headquarters located in New York, and Cambridge-based Intellia Therapeutics, which develops biopharmaceuticals, have jointly disclosed a novel therapy that specifically targets the faulty gene responsible for transthyretin amyloidosis.
United States Genome Editing Engineering Market Segmentation
United States Genome Editing Engineering Technology Outlook
- Meganucleases
- Cas9
- TALENs/MegaTALs
- ZFN
- Others
United States Genome Editing Engineering Delivery Method Outlook
United States Genome Editing Engineering Mode Outlook
United States Genome Editing Engineering End-use Outlook
- Biotechnology & Pharmaceutical Companies
- Academic & Government Research Institutes
- Contract Research Organizations
United States Genome Editing Engineering Application Outlook
- Genetic Engineering
- Clinical Applications
| Report Attribute/Metric |
Details |
| Market Size 2023 |
USD 3.12 Billion |
| Market Size 2024 |
USD 3.7 Billion |
| Market Size 2032 |
USD 13.69 Billion |
| Compound Annual Growth Rate (CAGR) |
15.63% (2023-2032) |
| Base Year |
2022 |
| Market Forecast Period |
2023-2032 |
| Historical Data |
2018-2022 |
| Market Forecast Units |
Value (USD Billion) |
| Report Coverage |
Revenue Forecast, Market Competitive Landscape, Growth Factors, and Trends |
| Segments Covered |
Technology, delivery method, application, mode, end-use |
| Countries Covered |
United States |
| Key Companies Profiled |
Intellia Therapeutics, Inc., Caribou Biosciences, Inc., Cellectis S.A., AstraZeneca, Takara Bio USA, Horizon Discovery Group plc, Integrated DNA Technologies, Inc., Egenesis Inc. |
| Key Market Opportunities |
· Extending use of CRISPR genome editing technology across a range of scientific domains · Rising demand for synthetic genes |
| Key Market Dynamics |
· Rising demand for synthetic genes and rising use of CRISPR genome · Technology for genome editing across a range of biotechnology domains |
Frequently Asked Questions (FAQ) :
The size of the United States Genome Editing Engineering market was estimated at USD 3.12 billion in 2023.
It is anticipated that the market would expand at a compound annual growth rate (CAGR) of 18.70% from 2023 to 2032.
The key players in the market are Intellia Therapeutics, Inc., Caribou Biosciences, Inc., Cellectis S.A., AstraZeneca, Takara Bio USA, Horizon Discovery Group plc, Integrated DNA Technologies, Inc., Egenesis Inc.
The Contract dominated the market in 2022.
The Ex-vivo category had the largest share of the market.
